110 related articles for article (PubMed ID: 9370558)
1. Indication-related dosing for magnetic resonance contrast media.
Yuh WT; Parker JR; Carvlin MJ
Eur Radiol; 1997; 7 Suppl 5():269-75. PubMed ID: 9370558
[TBL] [Abstract][Full Text] [Related]
2. Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.
Akeson P; Larsson EM; Kristoffersen DT; Jonsson E; Holtås S
Acta Radiol; 1995 May; 36(3):300-6. PubMed ID: 7742127
[TBL] [Abstract][Full Text] [Related]
3. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
Huang B; Liang CH; Liu HJ; Wang GY; Zhang SX
Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
[TBL] [Abstract][Full Text] [Related]
4. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
Runge VM; Lee C; Iten AL; Williams NM
Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
[TBL] [Abstract][Full Text] [Related]
5. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.
Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC
Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
Runge VM; Parker JR; Donovan M
Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
Runge VM
Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
[TBL] [Abstract][Full Text] [Related]
8. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.
Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
AJR Am J Roentgenol; 1994 Feb; 162(2):431-5. PubMed ID: 8310940
[TBL] [Abstract][Full Text] [Related]
9. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.
Essig M; Tartaro A; Tartaglione T; Pirovano G; Kirchin MA; Spinazzi A
Acad Radiol; 2006 Jun; 13(6):744-51. PubMed ID: 16679277
[TBL] [Abstract][Full Text] [Related]
10. Extracellular gadolinium-based contrast media: differences in diagnostic efficacy.
van der Molen AJ; Bellin MF
Eur J Radiol; 2008 May; 66(2):168-74. PubMed ID: 18372137
[TBL] [Abstract][Full Text] [Related]
11. MR imaging of the breast. Imaging and tissue characterization without intravenous contrast.
Santyr GE
Magn Reson Imaging Clin N Am; 1994 Nov; 2(4):673-90. PubMed ID: 7489316
[TBL] [Abstract][Full Text] [Related]
12. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.
Colosimo C; Demaerel P; Tortori-Donati P; Christophe C; Van Buchem M; Högström B; Pirovano G; Shen N; Kirchin MA; Spinazzi A
Pediatr Radiol; 2005 May; 35(5):501-10. PubMed ID: 15678342
[TBL] [Abstract][Full Text] [Related]
13. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol.
Runge VM; Wells JW; Nelson KL; Linville PM
J Magn Reson Imaging; 1994; 4(5):669-73. PubMed ID: 7981511
[TBL] [Abstract][Full Text] [Related]
14. Low-field interventional MRI in neurosurgery: finding the right dose of contrast medium.
Knauth M; Wirtz CR; Aras N; Sartor K
Neuroradiology; 2001 Mar; 43(3):254-8. PubMed ID: 11305762
[TBL] [Abstract][Full Text] [Related]
15. Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T--Initial Experience.
Krautmacher C; Willinek WA; Tschampa HJ; Born M; Träber F; Gieseke J; Textor HJ; Schild HH; Kuhl CK
Radiology; 2005 Dec; 237(3):1014-9. PubMed ID: 16237142
[TBL] [Abstract][Full Text] [Related]
16. Effects of contrast dose, delayed imaging, and magnetization transfer saturation on gadolinium-enhanced MR imaging of brain lesions.
Mathews VP; Caldemeyer KS; Ulmer JL; Nguyen H; Yuh WT
J Magn Reson Imaging; 1997; 7(1):14-22. PubMed ID: 9039589
[TBL] [Abstract][Full Text] [Related]
17. The optimal use of contrast agents at high field MRI.
Trattnig S; Pinker K; Ba-Ssalamah A; Nöbauer-Huhmann IM
Eur Radiol; 2006 Jun; 16(6):1280-7. PubMed ID: 16508769
[TBL] [Abstract][Full Text] [Related]
18. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
Runge VM; Armstrong MR; Barr RG; Berger BL; Czervionke LF; Gonzalez CF; Halford HH; Kanal E; Kuhn MJ; Levin JM; Low RN; Tanenbaum LN; Wang AM; Wong W; Yuh WT; Zoarski GH
Invest Radiol; 2001 Feb; 36(2):65-71. PubMed ID: 11224753
[TBL] [Abstract][Full Text] [Related]
19. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA
Radiology; 2018 Feb; 286(2):537-546. PubMed ID: 28880786
[TBL] [Abstract][Full Text] [Related]
20. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
